Literature DB >> 9185422

Antibiotic resistance pattern of Vibrio cholerae and Shigella causing diarrhoea outbreaks in the eastern Africa region: 1994-1996.

S F Materu1, O E Lema, H M Mukunza, C G Adhiambo, J Y Carter.   

Abstract

Between March 1994 and December 1996, 1797 rectal swabs were transported to the AMREF laboratory from sites in six countries in the eastern Africa region: 1749 were cultured for Vibrio cholerae and 48 for Shigella/Salmonella. Culture, isolation, identification and antibiotic susceptibility testing were performed using standardized techniques. The isolates were categorized as sensitive or resistant based on standardized zones of inhibition. The rate of isolation of V. cholerae from rectal swabs increased progressively from less than 20% to more than 45% between 1994 and 1996, 80-100% of isolates of V. cholerae from Kenya and south Sudan, and 65-90% from Somalia were sensitive to tetracycline, although in 1995 isolates from Mogadishu showed only 44% sensitivity. All isolates from Tanzania and Rwanda were 100% resistant to tetracycline. In Kenya and Somalia, the percentage of isolates sensitive to chloramphenicol and cotrimoxazole reduced markedly from 85% in 1994 to < 10% in 1996. 100% of isolates from Rwanda and Tanzania were resistant to chloramphenicol and cotrimoxazole while in south Sudan > 70% of isolates were sensitive. Nalidixic acid and erythromycin retained > 75% sensitivity in all areas. Shigella dysenteriae and Shigella flexneri were recovered from dysentery specimens in northern Kenya. Both species showed similar antibiotic sensitivity patterns and were sensitive only to nalidixic acid and furazolidone. Due to variations of resistance patterns within countries in the region, antibiotic sensitivity testing should be performed at the start of an outbreak, and antibiotic use should be restricted to severe cases of V. cholerae and Shigella infection.

Entities:  

Mesh:

Year:  1997        PMID: 9185422

Source DB:  PubMed          Journal:  East Afr Med J        ISSN: 0012-835X


  7 in total

1.  Cholera in endemic districts in Uganda during El Niño rains: 2002-2003.

Authors:  Scholastica O Alajo; Jessica Nakavuma; Joseph Erume
Journal:  Afr Health Sci       Date:  2006-06       Impact factor: 0.927

Review 2.  Quinolone use in the developing world: state of the art.

Authors:  T E Tupasi
Journal:  Drugs       Date:  1999       Impact factor: 9.546

3.  Emergence and rapid spread of tetracycline-resistant Vibrio cholerae strains, Madagascar.

Authors:  Jacques-Albert Dromigny; Olivat Rakoto-Alson; Davidra Rajaonatahina; René Migliani; Justin Ranjalahy; Philippe Mauclére
Journal:  Emerg Infect Dis       Date:  2002-03       Impact factor: 6.883

Review 4.  Epidemiology, genetics, and ecology of toxigenic Vibrio cholerae.

Authors:  S M Faruque; M J Albert; J J Mekalanos
Journal:  Microbiol Mol Biol Rev       Date:  1998-12       Impact factor: 11.056

5.  Antimicrobial Drug Resistance of Vibrio cholerae, Democratic Republic of the Congo.

Authors:  Berthe Miwanda; Sandra Moore; Jean-Jacques Muyembe; Georges Nguefack-Tsague; Ickel Kakongo Kabangwa; Daniel Yassa Ndjakani; Ankur Mutreja; Nicholas Thomson; Helene Thefenne; Eric Garnotel; Gaston Tshapenda; Denis Kandolo Kakongo; Guy Kalambayi; Renaud Piarroux
Journal:  Emerg Infect Dis       Date:  2015-05       Impact factor: 6.883

6.  Phenotypic and genetic characterization of Vibrio cholerae O1 isolated from various regions of Kenya between 2007 and 2010.

Authors:  Njeru Mercy; Ahmed Abade Mohamed; Ng'ang'a Zipporah; Goutam Chowdhury; Gururaja Perumal Pazhani; Thandavarayan Ramamurthy; Hamadi I Boga; Samuel M Kariuki; Oundo Joseph
Journal:  Pan Afr Med J       Date:  2014-09-04

7.  A cholera outbreak caused by drinking contaminated river water, Bulambuli District, Eastern Uganda, March 2016.

Authors:  Paul Edward Okello; Lilian Bulage; Alex Ario Riolexus; Daniel Kadobera; Benon Kwesiga; Henry Kajumbula; Muhamed Mulongo; Eunice Jennifer Namboozo; Godfrey Pimundu; Isaac Ssewanyana; Charles Kiyaga; Steven Aisu; Bao-Ping Zhu
Journal:  BMC Infect Dis       Date:  2019-06-11       Impact factor: 3.090

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.